A detailed history of Creative Planning transactions in Denali Therapeutics Inc. stock. As of the latest transaction made, Creative Planning holds 60,254 shares of DNLI stock, worth $1.4 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
60,254
Previous 43,033 40.02%
Holding current value
$1.4 Million
Previous $999,000 75.68%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 11, 2024

BUY
$20.96 - $31.05 $360,952 - $534,712
17,221 Added 40.02%
60,254 $1.76 Million
Q2 2024

Aug 15, 2024

BUY
$14.96 - $23.22 $51,731 - $80,294
3,458 Added 8.74%
43,033 $999,000
Q1 2024

May 10, 2024

BUY
$15.83 - $23.35 $233,729 - $344,762
14,765 Added 59.51%
39,575 $812,000
Q4 2023

Feb 14, 2024

BUY
$16.2 - $23.18 $168,382 - $240,932
10,394 Added 72.1%
24,810 $532,000
Q3 2023

Nov 16, 2023

BUY
$20.63 - $30.17 $4,435 - $6,486
215 Added 1.51%
14,416 $297,000
Q2 2023

Jul 21, 2023

BUY
$23.37 - $32.96 $90,044 - $126,994
3,853 Added 37.23%
14,201 $419,000
Q1 2023

May 15, 2023

BUY
$21.91 - $32.67 $63,078 - $94,056
2,879 Added 38.55%
10,348 $238,000
Q4 2022

Feb 10, 2023

BUY
$26.28 - $33.92 $4,756 - $6,139
181 Added 2.48%
7,469 $207,000
Q3 2022

Nov 03, 2022

BUY
$25.97 - $38.53 $5,531 - $8,206
213 Added 3.01%
7,288 $224,000
Q2 2022

Aug 15, 2022

BUY
$20.88 - $35.19 $6,159 - $10,381
295 Added 4.35%
7,075 $208,000
Q1 2022

May 16, 2022

BUY
$29.0 - $47.27 $45,588 - $74,308
1,572 Added 30.18%
6,780 $218,000
Q3 2021

Nov 10, 2021

BUY
$48.48 - $78.23 $252,483 - $407,421
5,208 New
5,208 $263,000
Q4 2020

Jan 29, 2021

SELL
$36.89 - $93.56 $408,741 - $1.04 Million
-11,080 Closed
0 $0
Q3 2020

Nov 05, 2020

BUY
$23.13 - $38.84 $256,280 - $430,347
11,080 New
11,080 $397,000

Others Institutions Holding DNLI

About Denali Therapeutics Inc.


  • Ticker DNLI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 134,174,000
  • Market Cap $3.13B
  • Description
  • Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...
More about DNLI
Track This Portfolio

Track Creative Planning Portfolio

Follow Creative Planning and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Creative Planning, based on Form 13F filings with the SEC.

News

Stay updated on Creative Planning with notifications on news.